CONMED EPS CNMD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $1.85
- Latest quarter, Q2 FY26
- $0.77
- +12% on a year earlier
- Fiscal year 2025
- $1.51
- −64% on the year before
CONMED's earnings per share was $1.85 over the twelve months to Jun 30, 2026, down 48% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.77, up 12% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 40% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.51 | −64% |
| FY2024 | $4.24 | +108% |
| FY2023 | $2.04 | n/a |
| FY2022 | −$2.83 | −246% |
| FY2021 | $1.94 | +593% |
| FY2020 | $0.28 | −71% |
| FY2019 | $0.95 | −33% |
| FY2018 | $1.41 | −28% |
| FY2017 | $1.97 | +279% |
| FY2016 | $0.52 | −53% |
| FY2015 | $1.10 | −5% |
| FY2014 | $1.16 | −9% |
| FY2013 | $1.27 | −10% |
| FY2012 | $1.41 | n/a |
| FY2011 | $0.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.77 | +12% | $1.85 | |
| Q1 FY26 | $0.45 | +137% | $1.77 | |
| Q4 FY25 | $0.54 | −50% | $1.51 | |
| Q3 FY25 | $0.09 | −94% | $2.05 | |
| Q2 FY25 | $0.69 | −28% | $3.53 | |
| Q1 FY25 | $0.19 | −70% | $3.80 | |
| Q4 FY24 | $1.08 | +3% | $4.24 | |
| Q3 FY24 | $1.57 | +214% | $4.21 | |
| Q2 FY24 | $0.96 | +123% | $3.14 | |
| Q1 FY24 | $0.63 | +950% | $2.61 | |
| Q4 FY23 | $1.05 | +21% | $2.04 | |
| Q3 FY23 | $0.50 | −66% | $1.86 |
Against its peers
Companies in Medical - Devices nearest CONMED's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CNMDCONMED | $1.85 | −48% a year |
| TMDXTransMedics | $3.84 | +99% a year |
| ITGRInteger | $3.66 | +61% a year |
| LIVNLivaNova | $3.39 | |
| ELMDElectromed | $1.31 | +56% a year |
| Peer median | $3.52 |
Where CONMED ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CONMED
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.